AgingResearch.NewsJoin free

Contrast-associated nephropathy

Disease

1 paper studies it1 finding

See all 1

  • Human trial1

Associations

1

Acetylcysteine

downin humans1

1 study

  1. Acetylcysteine lowers the risk of contrast-associated nephropathy in humans (9.6% vs 22.2%, P = .04).

    “CAN occurred in 9.6% of patients assigned to NAC and 22.2% of patients assigned to placebo (P =.04)”

    Human trialundergoing PCI or coronary angiographyoral2000 mg/dosen = 180

    N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up

    American heart journal

More on Acetylcysteine

Latest

Related